Breaking News

Novozymes Biopharma Builds cGMP bHA Facility

Novozymes Biopharma has begun construction of a new cGMP facility at its existing site in Tianjin, China, enabling the company to produce Bacillus-based Hyaluronic Acid (bHA), HyaCare, for the bio-medical and pharmaceutical industries.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novozymes Biopharma has begun construction of a new cGMP facility at its existing site in Tianjin, China, enabling the company to produce Bacillus-based Hyaluronic Acid (bHA), HyaCare, for the bio-medical and pharmaceutical industries. HyaCare is the first recombinant source of HA. The HyaCare process is free of animal-derived components and produced without the use of organic solvents. The company will invest more than $53 million in this new facility, which will produce bHA products to phar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters